HUMA News and Press, Humacyte Inc. From 05/09/24

2024-05-09 11:39:53 ET More on Humacyte Humacyte, Inc. (HUMA) Q4 2023 Earnings Call Transcript Humacyte GAAP EPS of -$0.24 in-line Humacyte stock dips after pricing stock offering to raise $40.2M Seeking Alpha’s Quant Rating on Humacyte Histori...

DURHAM, N.C., May 06, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the first quarter ended March 31, 2024, on Frida...

2024-04-22 16:53:54 ET Gainers: Oportun Financial  ( OPRT ) +5% . Humacyte ( HUMA ) +2% . Revance Therapeutics ( RVNC ) +2% . Office Properties Income  ( OPI ) +2% . Axcelis Technologies ( ACLS ) +1% . Losers: C...

2024-04-19 10:58:19 ET Humacyte (NASDAQ: HUMA) stock price is pumping this week. It jumped by over 10% on Friday, continuing a spectacular rally that started last week. It has soared by 40% from its lowest point this month and is trading at its highest point since February 29th. The...

DURHAM, N.C., March 26, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced it will host a virtual KOL event on Thursday, March 28, 2024 at 8:00 ...

2024-03-22 12:05:25 ET Humacyte, Inc. (HUMA) Q4 2023 Earnings Conference Call March 22, 2024 08:00 AM ET Company Participants Lauren Marek - Investor Relations, LifeSci Advisors Laura Niklason - President and Chief Executive Officer Dale Sander - Chief Financial ...

2024-03-22 07:02:17 ET More on Humacyte Humacyte stock dips after pricing stock offering to raise $40.2M Humacyte gains on FDA priority review for bioengineered blood vessel Seeking Alpha’s Quant Rating on Humacyte Historical earnings data for Humacyte...

Bitdeer Technologies Group (BTDR) is expected to report $0.11 for Q4 2023 BioForce Nanosciences Holdings Inc (BFNH) is expected to report for Q4 2023 Casino Guichard Perrachon ADR (CGUSY) is expected to report for quarter end 2023-12-31 Motorsport Games Inc. (MSGM) is expected to repo...

2024-03-21 11:15:47 ET More on Humacyte Humacyte stock dips after pricing stock offering to raise $40.2M Humacyte gains on FDA priority review for bioengineered blood vessel Seeking Alpha’s Quant Rating on Humacyte Historical earnings data for Humacyte...

DURHAM, N.C., March 18, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the fourth quarter and year ended December 31,...